Clinical Trial Update: A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1 and HER-2 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASLAN001 in recurrent/metastatic gastric cancer with HER-2 amplification or co-expression of HER-1 and HER-2 has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• ASLAN001

Snippet

Sponsor: ASLAN Pharmaceuticals | Conditions: Stomach Neoplasms, Cancer of Stomach | Phase 2 | Status: COMPLETED